INS and type 1 diabetes mellitus: In 2019, the European Medicines Agency (EMA) approved a first SGLT-2i and a first dual SGLT-1/-2i to improve glycaemic control, as an adjunctive treatment to insulin in people with type 1 diabetes and a BMI ≥ 27 kg/m2 [21].